Drug profile · INN
trastuzumab deruxtecan
ENHERTU
trastuzumab deruxtecan (ENHERTU) is a dna topoisomerase i inhibitor. Associated with AstraZeneca.
Drug details — trastuzumab deruxtecan
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 18
- Data quality
- 0.83
Quick answer
trastuzumab deruxtecan (ENHERTU) is a dna topoisomerase i inhibitor. Associated with AstraZeneca.
Key facts
Mechanism of action
DNA topoisomerase I inhibitor
Primary target: DNA topoisomerase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment
Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.
Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market
Novo Nordisk secures first-mover advantage launching Wegovy in China ahead of Eli Lilly's competing obesity drug, targeting massive untapped market opportunity.
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
This article delves into the EU market access landscape for Trastuzumab Deruxtecan, focusing on assessments by NICE, G-BA, and HAS for HER2-positive cancers.
Congress & event coverage
- Presentation2026 U.S.-Japan Healthcare
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trastuzumab deruxtecan?
trastuzumab deruxtecan (ENHERTU) is a dna topoisomerase i inhibitor. Associated with AstraZeneca.
What is the brand name for trastuzumab deruxtecan?
ENHERTU is a marketed brand name for trastuzumab deruxtecan. Check FDA Drugs@FDA for the current US label holder and prescribing information.